Capabilities
Our Digital Health group guides companies through the myriad considerations they encounter as the delivery of healthcare becomes increasingly digital.
As private equity investment in the Life Sciences and Healthcare industry continues to increase, our cohesive regulatory and transactional approach helps ensure success through each phase of investment.
We provide 360-degree support to companies that develop, manufacture and distribute products tailored specifically toward improving women’s health, from start-ups to global corporations.
Our Sunshine and State Law Compliance Group serves as a powerful industry advocate with respect to transparency laws for more than 100 members companies.
We established the Surprise Billing and Price Transparency Group to assist our clients in developing solutions to changes in healthcare transparency laws.
The K&S International Ad Hoc Group is a coalition of 20+ pharma and medical device companies that focuses on international transparency/disclosure laws targeting manufacturers.
May 1, 2025
FDA Releases Draft Guidance on Submission Recommendations for AI-Enabled Device Software Functions
April 4, 2025
FDA's LDT Rule Struck Down by Court: FDA Has Lost the Battle, But Is the War Over?
March 26, 2025
Saudi Arabia Permits Foreign Investment in Pharmacies
May 12, 2025
Former GE Healthcare, Fresenius Litigation & Compliance Leader Pat Murphy Joins King & Spalding in Washington, D.C.
May 6, 2025
Private equity and M&A partner Jason Osborn joins the firm’s Corporate practice group in New York
May 6, 2025
Private Equity and M&A Partner Jason Osborn Joins King & Spalding in New York